CR20200554A - Derivados sustituidos de la carboxamida dihidropirazolo pirazina - Google Patents
Derivados sustituidos de la carboxamida dihidropirazolo pirazinaInfo
- Publication number
- CR20200554A CR20200554A CR20200554A CR20200554A CR20200554A CR 20200554 A CR20200554 A CR 20200554A CR 20200554 A CR20200554 A CR 20200554A CR 20200554 A CR20200554 A CR 20200554A CR 20200554 A CR20200554 A CR 20200554A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dihydropyrazolo
- substituted
- carboxamide derivatives
- pyrazine carboxamide
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p> </p> <p>La invención se refiere a derivados sustituidos de la carboxamida dihidropirazolo pirazina y a su proceso de preparación, al igual que a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de trastornos cardiovasculares, preferentemente de trastornos trombóticos o tromboembólicos y diabetes, y también trastornos urogenitales y oftálmicos.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018087249 | 2018-05-17 | ||
PCT/EP2019/062005 WO2019219517A1 (en) | 2018-05-17 | 2019-05-10 | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200554A true CR20200554A (es) | 2021-01-12 |
Family
ID=66625151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200554A CR20200554A (es) | 2018-05-17 | 2019-05-10 | Derivados sustituidos de la carboxamida dihidropirazolo pirazina |
Country Status (25)
Country | Link |
---|---|
US (1) | US20220324865A1 (es) |
EP (1) | EP3793559A1 (es) |
JP (1) | JP2021523910A (es) |
KR (1) | KR20210013084A (es) |
CN (1) | CN112469412A (es) |
AR (1) | AR114906A1 (es) |
AU (1) | AU2019270142A1 (es) |
BR (1) | BR112020021612A2 (es) |
CA (1) | CA3100221A1 (es) |
CL (1) | CL2020002974A1 (es) |
CO (1) | CO2020014201A2 (es) |
CR (1) | CR20200554A (es) |
CU (1) | CU20200084A7 (es) |
EA (1) | EA202092779A1 (es) |
EC (1) | ECSP20072258A (es) |
JO (1) | JOP20200294A1 (es) |
MA (1) | MA52623A (es) |
MX (1) | MX2020012201A (es) |
NI (1) | NI202000083A (es) |
PE (1) | PE20210856A1 (es) |
PH (1) | PH12020551973A1 (es) |
SG (1) | SG11202010679SA (es) |
TW (1) | TW202012408A (es) |
UY (1) | UY38237A (es) |
WO (1) | WO2019219517A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
MD3755703T2 (ro) | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
WO2021094208A1 (en) * | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094210A1 (en) * | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
CN114236017B (zh) * | 2022-02-23 | 2022-06-07 | 深圳市海滨制药有限公司 | 一种棕榈酸抗坏血酸酯及其杂质的检测方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
JP2008502741A (ja) | 2004-06-09 | 2008-01-31 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
DE102004054665A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
DE102007032349A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
JP2010535773A (ja) | 2007-08-10 | 2010-11-25 | グラクソスミスクライン エルエルシー | ウイルス感染を治療するための窒素含有二環式化学物質 |
EP2220092B1 (en) | 2007-12-21 | 2012-06-06 | Genentech, Inc. | Azaindolizines and methods of use |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
MA34019B1 (fr) | 2010-02-27 | 2013-02-01 | Bayer Ip Gmbh | Aryltriazolone liée à un bis-aryle et son utilisation |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US9120805B2 (en) | 2012-03-28 | 2015-09-01 | Merck Patent Gmbh | Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity |
US20140275092A1 (en) | 2013-03-13 | 2014-09-18 | Constellation Pharmaceuticals, Inc. | Pyrazolo compounds and uses thereof |
JP6348582B2 (ja) * | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
JP6368367B2 (ja) * | 2013-10-30 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
US10189843B2 (en) | 2014-02-27 | 2019-01-29 | The University Of Tokyo | Fused pyrazole derivative having autotaxin inhibitory activity |
ES2697902T3 (es) | 2014-11-03 | 2019-01-29 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
JP6505956B2 (ja) | 2016-02-24 | 2019-04-24 | ファイザー・インク | JAK阻害剤としてのピラゾロ[1,5−a]ピラジン−4−イル誘導体 |
-
2019
- 2019-05-10 MX MX2020012201A patent/MX2020012201A/es unknown
- 2019-05-10 CA CA3100221A patent/CA3100221A1/en active Pending
- 2019-05-10 PE PE2020001842A patent/PE20210856A1/es unknown
- 2019-05-10 EA EA202092779A patent/EA202092779A1/ru unknown
- 2019-05-10 EP EP19725298.4A patent/EP3793559A1/en not_active Withdrawn
- 2019-05-10 JP JP2020564100A patent/JP2021523910A/ja active Pending
- 2019-05-10 CN CN201980046621.4A patent/CN112469412A/zh active Pending
- 2019-05-10 BR BR112020021612-7A patent/BR112020021612A2/pt not_active Application Discontinuation
- 2019-05-10 MA MA052623A patent/MA52623A/fr unknown
- 2019-05-10 WO PCT/EP2019/062005 patent/WO2019219517A1/en active Application Filing
- 2019-05-10 CR CR20200554A patent/CR20200554A/es unknown
- 2019-05-10 US US17/055,190 patent/US20220324865A1/en not_active Abandoned
- 2019-05-10 CU CU2020000084A patent/CU20200084A7/es unknown
- 2019-05-10 KR KR1020207035904A patent/KR20210013084A/ko unknown
- 2019-05-10 JO JOP/2020/0294A patent/JOP20200294A1/ar unknown
- 2019-05-10 SG SG11202010679SA patent/SG11202010679SA/en unknown
- 2019-05-10 AU AU2019270142A patent/AU2019270142A1/en not_active Abandoned
- 2019-05-15 TW TW108116681A patent/TW202012408A/zh unknown
- 2019-05-17 UY UY0001038237A patent/UY38237A/es not_active Application Discontinuation
- 2019-05-17 AR ARP190101323A patent/AR114906A1/es unknown
-
2020
- 2020-11-11 EC ECSENADI202072258A patent/ECSP20072258A/es unknown
- 2020-11-16 CL CL2020002974A patent/CL2020002974A1/es unknown
- 2020-11-17 CO CONC2020/0014201A patent/CO2020014201A2/es unknown
- 2020-11-17 NI NI202000083A patent/NI202000083A/es unknown
- 2020-11-18 PH PH12020551973A patent/PH12020551973A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA52623A (fr) | 2021-03-24 |
CO2020014201A2 (es) | 2021-03-08 |
CN112469412A (zh) | 2021-03-09 |
CU20200084A7 (es) | 2021-06-08 |
JP2021523910A (ja) | 2021-09-09 |
UY38237A (es) | 2019-11-29 |
US20220324865A1 (en) | 2022-10-13 |
ECSP20072258A (es) | 2020-12-31 |
TW202012408A (zh) | 2020-04-01 |
AR114906A1 (es) | 2020-10-28 |
NI202000083A (es) | 2021-03-11 |
BR112020021612A2 (pt) | 2021-01-26 |
WO2019219517A1 (en) | 2019-11-21 |
EA202092779A1 (ru) | 2021-02-02 |
KR20210013084A (ko) | 2021-02-03 |
AU2019270142A1 (en) | 2020-11-12 |
PH12020551973A1 (en) | 2021-08-02 |
PE20210856A1 (es) | 2021-05-18 |
CA3100221A1 (en) | 2019-11-21 |
MX2020012201A (es) | 2021-01-29 |
SG11202010679SA (en) | 2020-11-27 |
EP3793559A1 (en) | 2021-03-24 |
JOP20200294A1 (ar) | 2020-11-17 |
CL2020002974A1 (es) | 2021-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200554A (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
CL2018000039A1 (es) | Derivados de oxopiridina sustituidos | |
CR20150476A (es) | Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
CL2021001613A1 (es) | Derivados de oxopiridina sustituidos | |
PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
UY35746A (es) | Derivados de fenilalanina sustituidos | |
CR20150631A (es) | Benzoxazoles sustituidos | |
ECSP24024658A (es) | Derivados de s-alaninato sustituidos |